$PHAT
Phathom Pharmaceuticals, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023020109 Filed on May 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $18.94M $18.60M $20.25M
YoY Change -28.67% -8.14% 55.74%
% of Gross Profit
Research & Development $12.76M $11.48M $17.66M
YoY Change -32.16% -35.0% -14.19%
% of Gross Profit
Depreciation & Amortization $100.0K $146.0K $128.0K
YoY Change -32.89% 14.06% 2.4%
% of Gross Profit
Operating Expenses $31.70M $30.08M $37.91M
YoY Change -30.12% -20.65% 12.87%
Operating Profit -$31.70M -$30.08M -$37.91M
YoY Change -30.12% -20.65% 12.87%
Interest Expense $9.615M $9.217M $2.759M
YoY Change 69.67% 234.07% 116.9%
% of Operating Profit
Other Income/Expense, Net -$9.264M -$7.737M -$2.759M
YoY Change 66.71% 180.43% 119.14%
Pretax Income -$40.97M -$37.81M -$40.67M
YoY Change -19.55% -7.01% 16.72%
Income Tax
% Of Pretax Income
Net Earnings -$40.97M -$37.81M -$40.67M
YoY Change -19.55% -7.01% 16.71%
Net Earnings / Revenue
Basic Earnings Per Share -$0.84 -$0.89 -$1.07
Diluted Earnings Per Share -$0.84 -$0.89 -$1.069M
COMMON SHARES
Basic Shares Outstanding 43.61M 41.97M 31.71M
Diluted Shares Outstanding 48.50M 42.35M 38.04M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $248.8M $129.6M $138.1M
YoY Change 19.99% -6.17% -41.98%
Cash & Equivalents $248.8M $129.6M $138.1M
Short-Term Investments
Other Short-Term Assets $8.760M $10.27M $7.651M
YoY Change 369.71% 34.22% 59.4%
Inventory $111.0K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $257.7M $139.8M $145.7M
YoY Change 23.16% -4.05% -39.97%
LONG-TERM ASSETS
Property, Plant & Equipment $1.158M $1.275M $708.0K
YoY Change 31.14% 80.08% -77.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.749M $299.0K $805.0K
YoY Change 365.71% -62.86% 101.25%
Total Long-Term Assets $7.321M $4.167M $3.308M
YoY Change 72.46% 25.97% -8.11%
TOTAL ASSETS
Total Short-Term Assets $257.7M $139.8M $145.7M
Total Long-Term Assets $7.321M $4.167M $3.308M
Total Assets $265.0M $144.0M $149.0M
YoY Change 24.14% -3.38% -39.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.174M $4.805M $2.858M
YoY Change -27.51% 68.12% -73.78%
Accrued Expenses $15.45M $8.015M $7.565M
YoY Change 12.1% 5.95% -58.43%
Deferred Revenue $276.0K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $276.0K $0.00
YoY Change -100.0%
Total Short-Term Liabilities $21.55M $14.44M $11.39M
YoY Change 2.23% 26.76% -72.07%
LONG-TERM LIABILITIES
Long-Term Debt $97.81M $96.64M $91.04M
YoY Change 5.81% 6.15% 155.72%
Other Long-Term Liabilities $7.500M $7.500M $7.500M
YoY Change 0.0% 0.0% 33.93%
Total Long-Term Liabilities $105.3M $104.1M $98.54M
YoY Change 5.38% 5.68% 139.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.55M $14.44M $11.39M
Total Long-Term Liabilities $105.3M $104.1M $98.54M
Total Liabilities $247.4M $234.2M $111.0M
YoY Change 12.22% 110.97% 35.38%
SHAREHOLDERS EQUITY
Retained Earnings -$805.9M -$764.9M -$570.0M
YoY Change 29.78% 34.19%
Common Stock $823.5M $674.7M $608.1M
YoY Change 34.13% 10.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.60M -$90.20M $38.04M
YoY Change
Total Liabilities & Shareholders Equity $265.0M $144.0M $149.0M
YoY Change 24.14% -3.38% -39.51%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$40.97M -$37.81M -$40.67M
YoY Change -19.55% -7.01% 16.71%
Depreciation, Depletion And Amortization $100.0K $146.0K $128.0K
YoY Change -32.89% 14.06% 2.4%
Cash From Operating Activities -$22.20M -$39.67M -$45.10M
YoY Change -13.67% -12.05% -9.37%
INVESTING ACTIVITIES
Capital Expenditures $6.000K $214.0K $67.00K
YoY Change -101.4% 219.4% -60.36%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$6.000K -$214.0K -$67.00K
YoY Change -98.6% 219.4% -60.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 141.5M 14.07M 0.000
YoY Change 48.25% -100.0%
NET CHANGE
Cash From Operating Activities -22.20M -39.67M -45.10M
Cash From Investing Activities -6.000K -214.0K -67.00K
Cash From Financing Activities 141.5M 14.07M 0.000
Net Change In Cash 119.3M -25.81M -45.17M
YoY Change 72.14% -42.86% -8.79%
FREE CASH FLOW
Cash From Operating Activities -$22.20M -$39.67M -$45.10M
Capital Expenditures $6.000K $214.0K $67.00K
Free Cash Flow -$22.21M -$39.88M -$45.17M
YoY Change -12.19% -11.7% -9.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001783183
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39094
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
PHATHOM PHARMACEUTICALS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-4151574
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
100 Campus Drive
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 102
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Florham Park
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07932
CY2023Q1 dei City Area Code
CityAreaCode
877
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
742-8466
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
PHAT
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43614075
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
129574000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
155385000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10269000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5127000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
139843000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
160512000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1275000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1207000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2088000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2287000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
505000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
505000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
299000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
299000
CY2023Q1 us-gaap Assets
Assets
144010000
CY2022Q4 us-gaap Assets
Assets
164810000
CY2023Q1 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
78000
CY2022Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
35000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4805000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9997000
CY2023Q1 phat Accrued Expenses Related Parties Current
AccruedExpensesRelatedPartiesCurrent
2608000
CY2022Q4 phat Accrued Expenses Related Parties Current
AccruedExpensesRelatedPartiesCurrent
2499000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8015000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14678000
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
911000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
854000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
712000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
708000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
14443000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26237000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
96638000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
95264000
CY2023Q1 phat Revenue Interest Financing Liability Noncurrent
RevenueInterestFinancingLiabilityNoncurrent
114679000
CY2022Q4 phat Revenue Interest Financing Liability Noncurrent
RevenueInterestFinancingLiabilityNoncurrent
109525000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
945000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1098000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7500000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7500000
CY2023Q1 us-gaap Liabilities
Liabilities
234205000
CY2022Q4 us-gaap Liabilities
Liabilities
239624000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43602984
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41723308
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43571140
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41468871
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
19
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
19
CY2023Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
0
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
0
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
674708000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
652276000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-764907000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-727093000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-90195000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-74814000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
144010000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
164810000
CY2023Q1 phat Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
175000
CY2022Q1 phat Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
1430000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11479000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17660000
CY2023Q1 phat General And Administrative Expense Related Party
GeneralAndAdministrativeExpenseRelatedParty
3000
CY2022Q1 phat General And Administrative Expense Related Party
GeneralAndAdministrativeExpenseRelatedParty
0
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18598000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20246000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
30077000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
37906000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-30077000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-37906000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1460000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
7000
CY2023Q1 us-gaap Interest Expense
InterestExpense
9217000
CY2022Q1 us-gaap Interest Expense
InterestExpense
2759000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
20000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7737000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2759000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-37814000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-40665000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.89
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.89
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.07
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.07
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42354520
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42354520
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38036960
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38036960
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-74814000
CY2023Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
456000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7048000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
856000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14073000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-37814000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-90195000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
72156000
CY2022Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
254000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5775000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
515000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-40665000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
38035000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-37814000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-40665000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
146000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
128000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7048000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5775000
CY2023Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
877000
CY2022Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
848000
CY2023Q1 phat Accrued Interest On Revenue Interest Financing Liability
AccruedInterestOnRevenueInterestFinancingLiability
5154000
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
496000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
518000
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-763000
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-591000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5143000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4384000
CY2023Q1 phat Increase Decrease In Accounts Payable And Accrued Expenses Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties
137000
CY2022Q1 phat Increase Decrease In Accounts Payable And Accrued Expenses Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties
2719000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-11303000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-6075000
CY2022Q1 phat Increase Decrease In Clinical Accrued Trial Expenses
IncreaseDecreaseInClinicalAccruedTrialExpenses
-1402000
CY2023Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
57000
CY2022Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
4000
CY2023Q1 phat Increase Decrease In Operating Right Of Use Asset And Lease Liabilities
IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities
50000
CY2022Q1 phat Increase Decrease In Operating Right Of Use Asset And Lease Liabilities
IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities
22000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
117000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39669000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44757000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
214000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-214000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-67000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14072000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25811000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-44824000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
155890000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
183419000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
130079000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
138595000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
2546000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
1388000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
120000
CY2023Q1 phat Non Cash Settlement Of Employee Stock Purchase Plan Liability In Common Stock
NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock
856000
CY2022Q1 phat Non Cash Settlement Of Employee Stock Purchase Plan Liability In Common Stock
NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock
515000
CY2023Q1 phat Non Cash Settlement Of Defined Contribution Plan Liability In Common Stock
NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock
456000
CY2022Q1 phat Non Cash Settlement Of Defined Contribution Plan Liability In Common Stock
NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock
254000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to accruals for research and development expenses and the valuation of various equity instruments. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</span></p>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p>
CY2023Q1 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2023Q1 phat Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2497000
CY2022Q4 phat Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3080000
CY2023Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3490000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
8447000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1972000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3000000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
56000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
151000
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2892000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2678000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1617000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1471000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1275000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1207000
CY2023Q1 us-gaap Depreciation
Depreciation
100000
CY2022Q1 us-gaap Depreciation
Depreciation
100000
CY2023Q1 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2022 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8015000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14678000
CY2023Q1 phat Accounts Payable And Accrued Expenses Related Parties Current
AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
17000000
CY2022Q4 phat Accounts Payable And Accrued Expenses Related Parties Current
AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
15000000
CY2023Q1 phat Purchase Commitment Expense
PurchaseCommitmentExpense
0
CY2022Q1 phat Purchase Commitment Expense
PurchaseCommitmentExpense
0
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2088000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2287000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2088000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2287000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
712000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
708000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
945000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1098000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1657000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1806000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
552000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
753000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
513000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1818000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
161000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1657000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
712000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
945000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0820
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
200000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2023Q1 phat Long Term Debt Noncurrent Excluding Unamortized Debt Discount
LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount
105351000
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
8713000
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
96638000
CY2023Q1 phat Long Term Debt Maturities Repayments Of Principal And Interest Due Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths
0
CY2023Q1 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo
0
CY2023Q1 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree
29707000
CY2023Q1 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour
94764000
CY2023Q1 phat Long Term Debt And Interest
LongTermDebtAndInterest
124471000
CY2023Q1 phat Debt Instrument Interest And Final Payment Fee
DebtInstrumentInterestAndFinalPaymentFee
24471000
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
100000000
CY2023Q1 phat Investors Right To Receive Royalties Termination Description
InvestorsRightToReceiveRoyaltiesTerminationDescription
The investors’ right to receive royalties on net sales will terminate when the investors have aggregate payments equal to 200% of the Investment Amount. In addition, at any time after the earlier of (i) April 30, 2024 and (ii) the date that the payment for Erosive GERD regulatory approval is made, the Company has the right to make a cap payment equal to 200% of the Investment Amount less any royalties already paid, at which time the agreement will terminate.
CY2023Q1 phat Investors Receipt Description
InvestorsReceiptDescription
If the investors have not received aggregate payments of at least 100% of the Investment Amount by December 31, 2028, and at least 200% of the Investment Amount by December 31, 2037, each a Minimum Amount, then the Company will be obligated to make a cash payment to the investors in an amount sufficient to gross the investors up to the applicable Minimum Amount.
CY2023Q1 phat Default Obligation Description
DefaultObligationDescription
Upon the occurrence of an event of default taking place prior to April 1, 2025, between April 1, 2025, and April 1, 2028, and after April 1, 2028, the Company is obligated to pay 1.30 times Investment Amount, 1.65 times Investment Amount, and 2.0 times investment amount, respectively, less any amounts the Company previously paid pursuant to the agreement.
CY2023Q1 phat Change In Control Description
ChangeInControlDescription
Upon the occurrence of a change in control event taking place prior to the earlier of April 1, 2024, or FDA approval of vonoprazan for Erosive GERD, the Company is obligated to pay 200% of the Investment Amount plus either 15% of the Investment Amount if occurrence prior to May 3, 2023, or plus 30% of the Investment Amount if occurrence thereafter.
CY2023Q1 phat Gross Proceeds From Revenue Interest Financing Agreement
GrossProceedsFromRevenueInterestFinancingAgreement
100000000.0
CY2023Q1 phat Payment Of Transaction Costs
PaymentOfTransactionCosts
4600000
CY2023Q1 phat Net Proceeds From Revenue Interest Financing Transaction
NetProceedsFromRevenueInterestFinancingTransaction
95400000
CY2023Q1 phat Revenue Interest Financing Liability
RevenueInterestFinancingLiability
114700000
CY2023Q1 phat Gross Proceeds From Revenue Interest Financing Agreement
GrossProceedsFromRevenueInterestFinancingAgreement
100000000
CY2023Q1 phat Payment Of Transaction Costs
PaymentOfTransactionCosts
4554000
phat Interest Expense Related To Revenue Interest Financing Liability
InterestExpenseRelatedToRevenueInterestFinancingLiability
19233000
CY2023Q1 phat Revenue Interest Financing Liability
RevenueInterestFinancingLiability
114679000
CY2023Q1 phat Interest Expense Related To Revenue Interest Financing Liability
InterestExpenseRelatedToRevenueInterestFinancingLiability
5200000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
254437
CY2023Q1 phat Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Share Vesting
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting
222593
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
31844
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10868359
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
800000
CY2022Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000
CY2023Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.75
CY2021Q3 phat Defined Contribution Plan Employer Discretionary Match Number Of Shares Settled
DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled
18394
CY2022Q1 phat Defined Contribution Plan Employer Discretionary Match Number Of Shares Settled
DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled
16756
CY2022Q3 phat Defined Contribution Plan Employer Discretionary Match Number Of Shares Settled
DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled
84784
CY2023Q1 phat Defined Contribution Plan Employer Discretionary Match Number Of Shares Settled
DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled
52130
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5586470
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.40
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4476000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1043660
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.38
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
25965
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
34.66
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6604165
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.98
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
170000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3019036
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
23.99
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M8D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
138000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
37300000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M6D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6377
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6619
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0346
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0170
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7048000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5775000

Files In Submission

Name View Source Status
phat-20230331_def.xml Edgar Link unprocessable
phat-20230331_pre.xml Edgar Link unprocessable
0000950170-23-020109-index-headers.html Edgar Link pending
0000950170-23-020109-index.html Edgar Link pending
0000950170-23-020109.txt Edgar Link pending
0000950170-23-020109-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
phat-20230331.htm Edgar Link pending
phat-20230331.xsd Edgar Link pending
phat-ex10_1.htm Edgar Link pending
phat-ex31_1.htm Edgar Link pending
phat-ex31_2.htm Edgar Link pending
phat-ex32_1.htm Edgar Link pending
phat-ex32_2.htm Edgar Link pending
phat-ex4_5.htm Edgar Link pending
phat-ex4_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
phat-20230331_lab.xml Edgar Link unprocessable
phat-20230331_cal.xml Edgar Link unprocessable
phat-20230331_htm.xml Edgar Link completed
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending